Charles River Laboratories (CRL) and Akron Bio said Thursday they integrated Akron's current Closed System Solutions liquid cytokines into Charles River's Cell Therapy Flex Platform to improve cancer treatment platform.
Using closed systems can simplify the production process, minimize risk, and boost the overall reliability of cell therapy manufacturing, the company said.
Adding liquid cytokines to the Flex Platform could reduce labor requirements, strengthen processes, and ultimately lower risks for patients, Charles River's Senior Vice President Kerstin Dolph added.
Price: 165.26, Change: -8.65, Percent Change: -4.97
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.